Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.5% – Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price rose 11.5% on Friday . The company traded as high as $0.45 and last traded at $0.42. Approximately 34,499,859 shares traded hands during trading, a decline of 67% from the average daily volume of 103,399,938 shares. The stock had previously closed at $0.38.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Sunday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Trading Up 14.2 %

The firm has a market cap of $80.01 million, a P/E ratio of -0.01 and a beta of 2.02. The stock has a 50 day simple moving average of $0.30 and a 200-day simple moving average of $0.28. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. On average, equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.